Coherus BioSciences Non-GAAP EPS of -$0.34 misses by $0.03, revenue of $12.7M misses by $1.39M
Source: SeekingAlpha
2026-03-09 16:23:51 ET
More on Coherus BioSciences
- Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114
- Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Coherus Oncology: A Two-Pronged March With Mid-2026 Implications
- Coherus BioSciences Q4 2025 Earnings Preview
- Coherus Oncology prices stock offering to raise $50.1M
Read the full article on Seeking Alpha
For further details see:
Coherus BioSciences Non-GAAP EPS of -$0.34 misses by $0.03, revenue of $12.7M misses by $1.39M
Coherus BioSciences Inc.
NASDAQ: CHRS
CHRS Trading
1.05% G/L:
$1.93 Last:
1,799,290 Volume:
$1.86 Open:
CHRS Latest News
March 09, 2026 04:15:00 pm
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
March 02, 2026 09:30:00 am
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
February 17, 2026 04:11:28 pm
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
CHRS Stock Data
$262,894,453
111,104,635
0.81%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
